Fora Capital, LLC Allakos Inc. Transaction History

Fora Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $22,623 - $30,236	-265 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $415,657 - $582,064	-3,788 Reduced 93.46%	265 $30 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $322,537 - $617,879	4,053 New	4,053 $567,000
Q3 2020 Nov 13, 2020	SELL	$66.43 - $90.99 $146,943 - $201,269	-2,212 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $52,671 - $96,505	-1,196 Reduced 35.09%	2,212 $159 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $39,195 - $82,276	-881 Reduced 20.54%	3,408 $151,000
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $285,175 - $590,723	4,289 New	4,289 $408,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $103M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.